Researchers at the University of Ottawa (uOttawa) say while recent research shows breast cancer cases are on the rise among younger Canadians (Link), early diagnosis not only saves lives, but also saves the country s healthcare system nearly $500 million.
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4.